Abstract
Multiple lines of evidence suggest that hypofunction of glutamatergic neurotransmission via N-methyl-Daspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia. The NMDA receptor hypofunction hypothesis of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a potential new strategy for the management of schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory sites through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. With the aim of treating schizophrenia, a number of pharmaceutical industries have developed novel and selective GlyT-1 inhibitors, and recent studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methyl glycine) could be a potential drug. The present review considers GlyT-1 inhibitors as novel drugs for the treatment of schizophrenia.
Keywords: Schizophrenia, NMDA receptor, glutamate, glycine, transporter, glia
Central Nervous System Agents in Medicinal Chemistry
Title: Glycine Transporter-1 Inhibitors as Novel Therapeutic Drugs for Schizophrenia
Volume: 7 Issue: 3
Author(s): Kenji Hashimoto
Affiliation:
Keywords: Schizophrenia, NMDA receptor, glutamate, glycine, transporter, glia
Abstract: Multiple lines of evidence suggest that hypofunction of glutamatergic neurotransmission via N-methyl-Daspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia. The NMDA receptor hypofunction hypothesis of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a potential new strategy for the management of schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory sites through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. With the aim of treating schizophrenia, a number of pharmaceutical industries have developed novel and selective GlyT-1 inhibitors, and recent studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methyl glycine) could be a potential drug. The present review considers GlyT-1 inhibitors as novel drugs for the treatment of schizophrenia.
Export Options
About this article
Cite this article as:
Hashimoto Kenji, Glycine Transporter-1 Inhibitors as Novel Therapeutic Drugs for Schizophrenia, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152407781669161
DOI https://dx.doi.org/10.2174/187152407781669161 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial - Coping with Neuropathic Pain: Do We Need More Selective Analgesic Drugs?
Current Pharmaceutical Design Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain
Current Medicinal Chemistry Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Chronic Obstructive Pulmonary Disease and Respiratory Acidosis in the Intensive Care Unit
Current Respiratory Medicine Reviews Stereoselectivity in Drug Metabolism: Molecular Mechanisms and Analytical Methods
Current Drug Metabolism The Effect of Pomegranate Juice on the Expression of Some Murine UDP-Glucuronosyltransferases Genes
Drug Metabolism Letters Induction of Apoptotic Cell Death in Tumor Cells by S100A8/A9 Released from Inflammatory Cells Upon Cellular Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Editorial: Systems Genetics of Alzheimer’s Disease: From GWAS to Disease Pathways
Current Alzheimer Research Semantic Intrusions and Failure to Recover From Semantic Interference in Mild Cognitive Impairment: Relationship to Amyloid and Cortical Thickness
Current Alzheimer Research Childhood Maltreatment and Stress-Related Psychopathology: The Epigenetic Memory Hypothesis
Current Pharmaceutical Design Plants Indicated by Brazilian Indians for Disturbances of the Central Nervous System: A Bibliographical Survey
Central Nervous System Agents in Medicinal Chemistry Recent Advances in the Rationale Design of GPER Ligands
Current Medicinal Chemistry The Functional Role of CYP2B6 in Human Drug Metabolism: Substrates and Inhibitors In Vitro, In Vivo and In Silico
Current Drug Metabolism Editorial (Thematic Selection: 'Glutamatergic-based Rapid Acting Antidepressants: The Link to Synaptic Plasticity')
Current Neuropharmacology Early Apoptotic Vascular Signaling is Determined by Sirt1 Through Nuclear Shuttling, Forkhead Trafficking, Bad, and Mitochondrial Caspase Activation
Current Neurovascular Research The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry